Get the Stockscreener App
87.09
0.99%
0.7992
Rhythm Pharmaceuticals Inc stock is traded at $87.09, with a volume of 189.72K.
It is up +0.99% in the last 24 hours and down -6.82% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$86.29
Open:
$85.97
24h Volume:
189.72K
Relative Volume:
0.23
Market Cap:
$5.95B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-28.01
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
+12.80%
1M Performance:
-6.82%
6M Performance:
-10.95%
1Y Performance:
+85.60%
1-Day Range:
$85.97
$88.79
1-Week Range:
$78.38
$90.80
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
87.14 | 5.89B | 189.76M | -196.54M | -156.63M | -3.1087 |
VRTX
Vertex Pharmaceuticals Inc
|
439.78 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.52 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
752.04 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.70 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.62 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - msn.com
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - msn.com
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance Singapore
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Canada
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
Rhythm Pharmaceuticals Announces Appointment of Kim Popovits as Director and Departure of Ed Mathers - Quiver Quantitative
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Strength seen in Rhythm Pharmaceuticals (RYTM): Can its 12.6% jump turn into more strength? - MSN
Rhythm posts first FDA approval for acquired hypothalamic obesity - Longevity.Technology
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - qz.com
Rhythm Pharma higher after FDA label expansion for lead drug - msn.com
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025News and Statistics - indexbox.io
Rhythm Pharma wins EU backing to expand Imcivree label - msn.com
Discipline and Rules-Based Execution in RYTM Response - Stock Traders Daily
RYTM PE Ratio & Valuation, Is RYTM Overvalued - intellectia.ai
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval - timothysykes.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 10.9% HigherShould You Buy? - MarketBeat
Rhythm Pharmaceuticals Surges After FDA Approval for Obesity Treatment - StocksToTrade
Jefferies Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $125 - Moomoo
FDA’s Approval Sparks Optimism for Rhythm Pharmaceuticals - StocksToTrade
-7.42% for Rhythm Pharmaceuticals stock as sellers dominate near key support - Traders Union
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity - Sahm
Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharma down as FDA extends review period for Imcivree label expansion - msn.com
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $158 - Moomoo
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion - TipRanks
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Leerink reiterates Rhythm Pharmaceuticals stock rating on CHMP opinion By Investing.com - Investing.com Canada
Rhythm grabs a new obesity approval; how it edged in where Lilly, Novo have fallen flat - msn.com
Short Squeeze: What is the earnings history of Rhythm Pharmaceuticals IncWeekly Trend Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for - globenewswire.com
EU panel backs Rhythm drug for obesity and hunger after brain injury - Stock Titan
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - Bitget
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
TD Cowen reiterates Buy on Rhythm Pharmaceuticals stock at $130 - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
Mar 04 '26 |
Sale |
89.56 |
5,614 |
502,790 |
160 |
1.90%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):